Announced

BioNTech to acquire CureVac for $1.25bn.

Synopsis

BioNTech, an immunotherapy company, agreed to acquire CureVac, a biotech company, for $1.25bn. “This transaction is another building block in BioNTech’s oncology strategy and an investment in the future of cancer medicine. We intend to bring together complementary capabilities and leverage technologies with the goal of advancing the development of innovative and transformative cancer treatments and establishing new standards of care for various types of cancer in the coming years,” Ugur Sahin, BioNTech CEO and Co-Founder.

Show Details & Financials

Did you work on this deal?

Claim Deal

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Claim Deal

All rights reserved. Copyright © 2025 Datasite

MergerLinks - BioNTech to acquire CureVac for $1.25bn.